Cantor Fitzgerald Forecasts Weaker Earnings for Zura Bio

Zura Bio Limited (NASDAQ:ZURA) – Research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Zura Bio in a research report issued on Wednesday, March 26th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of ($0.45) per share for the year, down from their previous forecast of ($0.40). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.09. The business had revenue of $0.00 million during the quarter.

Several other research analysts have also weighed in on the stock. Guggenheim reiterated a “buy” rating and issued a $15.00 price objective on shares of Zura Bio in a research note on Wednesday. Oppenheimer reiterated an “outperform” rating and set a $19.00 price objective (down from $20.00) on shares of Zura Bio in a report on Wednesday. Chardan Capital reduced their price objective on Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $15.00.

Zura Bio Trading Down 6.6 %

Shares of ZURA opened at $1.27 on Friday. The business’s 50-day moving average is $1.46 and its 200-day moving average is $2.73. Zura Bio has a fifty-two week low of $1.07 and a fifty-two week high of $6.35.

Hedge Funds Weigh In On Zura Bio

Institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. acquired a new position in shares of Zura Bio during the 4th quarter valued at about $27,000. Prudential Financial Inc. bought a new stake in Zura Bio during the fourth quarter worth approximately $28,000. Two Sigma Advisers LP acquired a new position in Zura Bio during the fourth quarter valued at approximately $32,000. ProShare Advisors LLC acquired a new position in Zura Bio during the fourth quarter valued at approximately $35,000. Finally, XTX Topco Ltd bought a new position in shares of Zura Bio in the fourth quarter valued at approximately $44,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.